Physician profile
Douglas E Schultz
NPI 1487631859
$13,953.55
in general payments reported to CMS, 2019-2025
52 companies · $6,430 in 2025
The $6,430 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $1,101 · 2021: $1,406 · 2022: $1,035 · 2023: $773 · 2024: $1,157 · 2025: $6,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,304 · Food and Beverage: $3,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,304.00 |
| Food and Beverage | $3,056.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,304.00 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,355.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $902.61 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $898.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $834.59 | 2019-2025 | |
| Abbvie INC. | $685.65 | 2019-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.83 | 2019-2025 | Jardiance |
| Amgen INC. | $409.25 | 2019-2025 | Repatha, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $315.98 | 2019-2022 | |
| Amarin Pharma, INC. | $228.04 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.16 | 2019-2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $162.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $159.19 | 2020-2025 | Verquvo, Belsomra, Capvaxive |
| Glaxosmithkline, LLC. | $151.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $135.42 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.